CCT361814, also known as NXP800, is a a potent and orally bioavailable HSF1 Pathway Inhibitor, which caused tumor regression in a human ovarian adenocarcinoma xenograft model with on-pathway biomarker modulation and a clean in vitro safety profile. CCT361814 displayed a good PK profile across different species and excellent therapeutic efficacy, including tumor regression, from a low free exposure in an in vivo human ovarian cancer xenograft mouse model, and demonstrated biomarker modulation in tumor tissue consistent with the HSF1 pathway inhibition─representing overall a strong pharmacological audit trail.
MedKoo Cat#: 123133
Name: CCT361814
CAS#: 1693734-80-3
Chemical Formula: C32H32FN5O4
Exact Mass: 569.2438
Molecular Weight: 569.64
Elemental Analysis: C, 67.47; H, 5.66; F, 3.34; N, 12.29; O, 11.23
The following data is based on the product molecular weight 569.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
